sera – Page 18 – Communicable Diseases Research

Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination

BNT162b2 COVID-19 mRNA 백신 접종 후 6개월 후의 SARS-CoV-2 변이체에 대한 백신 유도 항체 반응

Article

Published on 2022-04-272022-09-11
Journal: Microbiology Spectrum [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves

처음 3개의 전염병 파동 동안 태국 성인에서 항 SARS-CoV-2 항체의 혈청 유병률

Article

Published on 2022-04-272022-09-11
Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody assays chemiluminescence immunoassay Community Contact tracing coronavirus coronavirus disease Coronavirus disease-19 country COVID-19 COVID-19 outbreak COVID-19 patient COVID-19 patients delta variant disease onset Disease prevalence driver Epidemic epidemic wave epidemic waves Health IgG IgG antibodies immunofluorescence assay individual individuals infection rate microneutralization N protein Neutralizing antibodies numbers of patient participant patients performed Prevalence Public public transport recruited risk SARS-CoV-2 sera seropositive Seropositivity Seroprevalence serum samples Support tested Thai people the N protein the patient Transport with COVID-19
[DOI] 10.1371/journal.pone.0263316 PMC 바로가기 [Article Type] Article

Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection

Research

Published on 2022-04-272022-10-05
Journal: Nature Communications [Category] COVID19(2023년), SARS, 임상, 치료기술, 치료법,

Rapid Detection of Anti-SARS-CoV-2 Antibodies with a Screen-Printed Electrode Modified with a Spike Glycoprotein Epitope

스파이크 당단백질 에피토프로 변형된 스크린 인쇄 전극을 사용한 항 SARS-CoV-2 항체의 신속한 검출

Article

Published on 2022-04-262022-09-11
Journal: Biosensors [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, 치료제,

[키워드] 2019 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody B-cell epitope capture caused Chagas disease Chikungunya Consequences coronavirus coronavirus disease COVID-19 cross-reaction Dengue detection diagnose diagnoses diagnosing Diagnostic method differentiation dilution factor electrochemical biosensor electrode epitope Final flexibility Health hydroquinone IgG immunocomplex Immunoglobulin Immunoglobulin G immunological immunological diagnostic individual Infection linear material Molecular biology non-infected other disease other diseases pandemic Pathogens patient sera point of care Rapid reaction required respiratory SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike glycoprotein SARS-CoV-2-specific IgG SARS-CoV-2-specific IgGs selectivity sera serological serum samples severe acute respiratory syndrome Coronavirus specificity spike spike glycoprotein Spike protein Spread synthesis the SARS-CoV-2 the spike protein variants of SARS-CoV-2 Volume was measured was selected
[DOI] 10.3390/bios12050272 PMC 바로가기 [Article Type] Article

Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants

BA.1 및 BA.2 Omicron 변이체에 대한 Pfizer/BioNTech SARS-CoV-2 mRNA 3차 부스터 백신 용량의 안전성 및 면역원성

Clinical and Translational Article

Published on 2022-04-262022-09-14
Journal: Med (New York, N.Y.) [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단,

[키워드] Abstract adverse event AMED anti-spike antibody BA.1 BA.1.1 BA.2 BNT162b2 mRNA vaccine booster booster vaccination Booster vaccine breadth changes in Context cross-reactivity cytokine cytokine signature Delta dose evaluate evaluated finding funding groups healthcare worker Humoral immunity immunogenicity increase increase in individual Japan Live virus microneutralization mRNA mRNA vaccination Mutation neutralization neutralization ability Neutralization antibody neutralization titer Neutralizing Neutralizing antibodies neutralizing antibody no significant difference omicron Pfizer/BioNTech robust Safe Safety SARS-CoV-2 SARS-CoV-2 variants second vaccination sera significantly lower Spike protein subvariant supported the spike protein vaccination Vaccine vaccine dose Vaccine-induced immunity vaccinee variant variant of concern variants variants of concern VoC VOCs
[DOI] 10.1016/j.medj.2022.04.013 PMC 바로가기 [Article Type] Clinical and Translational Article

Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion

세포 진입 및 면역 회피에 의한 SARS-CoV-2 변이체 B.1.617.1(카파), B.1.617.2(델타) 및 B.1.618의 특성화

Article

Published on 2022-04-262022-09-11
Journal: mBio [Category] COVID19(2023년), SARS, 변종, 치료제,

[키워드] ACE2 ACE2 decoy receptor ACE2 orthologs ACE2 receptor acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition alteration angiotensin antibody Antiviral B.1.617.1 B.1.617.2 B.1.618 binding binding affinity causative agent cell entry characterization cleavage contribute convalescent sera coronavirus COVID-19 Delta delta variant E484K Efficiency Entry inhibitor entry inhibitors examined exhibited facilitate highlight host tropism human Angiotensin-converting enzyme Human angiotensin-converting enzyme 2 immune Immunity India Kappa variant L452R marmoset mouse Mutation neutralization neutralization antibodies Neutralization antibody neutralization titer Neutralizing antibodies neutralizing antibody P681R pandemic Patient receptor reduced SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sensitivity sera significantly increased Spike protein Spike proteins Spread T478K the spike protein Transmissibility vaccinated individual vaccinated individuals variant variants viral entry wild-type
[DOI] 10.1128/mbio.00099-22 PMC 바로가기 [Article Type] Article

Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients

SARS-CoV-2에 대한 초기의 강력한 항체 반응은 COVID-19 환자의 질병 중증도를 예측합니다

Article

Published on 2022-04-152022-09-11
Journal: Journal of Translational Medicine [Category] COVID19(2023년), SARS, 바이오마커, 진단, 치료법,

[키워드] antibody antibody levels Antibody profile Antibody Response Antibody responses Antibody-dependent enhancement Antigen Antigen microarray Biomarker Candidates cell activation Clinical significance correlated COVID-19 COVID-19 patient disease disease severity elicit epidemiological studies exacerbate frequencies Frequency full length healthy controls idea IgA IgA response IgA responses IgE IgG IgM response IgM responses implication levels of antibody mast cell Mast cells Mild disease MOST nonstructural protein nucleocapsid Pathogenesis pathogenesis of COVID-19 Patient patients with COVID-19 peak levels Planning predict Prevalence Prognosis prognostic Protein recent response Result risk S protein SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens sera serological studies SEROLOGICAL STUDY Serum level severe disease severity Spread Support testing antibody the disease the vaccine vaccine candidates virus with mild disease
[DOI] 10.1186/s12967-022-03382-y PMC 바로가기 [Article Type] Article

Systematic profiling of antigen bias in humoral response against SARS-CoV-2

SARS-CoV-2에 대한 체액 반응의 항원 편향에 대한 체계적인 프로파일링

Article

Published on 2022-04-152022-09-11
Journal: Virus research [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination

우려되는 SARS-CoV-2 감마 및 델타 변이체가 BNT162b2 mRNA 백신 접종에 대한 반응으로 생성된 중화 활성을 약화시킬 수 있음

Article

Published on 2022-04-152022-09-11
Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 진단,

Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity

SARS-CoV-2 변이체의 스파이크 기능 분석, 중화 가능성 및 바이러스 감염성에서 뚜렷한 돌연변이의 역할 밝혀

Article

Published on 2022-04-132022-09-11
Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] Affect Analysis approach carried circulating viral variants cleavage site conjunction COVID-19 defined Delta Disease progression dose E484K Efficacy enhanced escape FCS functional furin furin cleavage site furin–cleavage site in viral Infectivity Lota Mutation N501Y neutralization neutralization antibodies Neutralizing antibodies neutralizing antibody no effect no effects P681H P681R Pfizer Pfizer–BTN162b2 vaccine Potential promote pseudovirus pseudoviruses RBD RBD mutation RBD mutations Receptor binding domain receptor binding domain (RBD) reduce reveal role SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sensitivity sera Site specific spike mutation specific spike mutations spike spike mutation spike mutations Spread vaccinated individuals Vaccine Viral viral infectivity Viral transmission viral variant Viral variants
[DOI] 10.3390/v14040803 PMC 바로가기 [Article Type] Article